Amneal Pharmaceuticals Inc - Class A
Research Amneal Pharmaceuticals Inc - Class A (AMRX) on Bullrun: valuation model: 35.6% overvalued, market cap USD 5.72B, P/E 37.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAMRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal35.6% overvalued
- Market capUSD 5.72B
- P/E37.4
- Financial periodQ2 2026
- RevenueUSD 796.20M
- Net incomeUSD 57.66M
- Free cash flow-USD 143.99M
- Gross margin42.0%
Valuation Snapshot
Bullrun's latest valuation model marks Amneal Pharmaceuticals Inc - Class A as 35.6% overvalued; latest market cap is USD 5.72B; P/E is 37.4.
Peer valuation comparison
Latest P/E is 37.4x versus a Healthcare sector median of 24.46x (52.9% above).
Latest P/E is 37.4x versus a United States median of 24.87x (50.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.02B | USD 72.06M | USD 269.93M | 36.9% | 0.22 | USD 282.03M | USD 2.57B | -USD 70.79M |
| FY2024 | USD 2.79B | -USD 116.89M | USD 243.18M | 36.5% | -0.38 | USD 110.55M | USD 2.39B | -USD 109.27M |
| FY2023 | USD 2.39B | -USD 83.99M | USD 302.36M | 34.3% | -0.48 | USD 91.54M | USD 2.42B | USD 19.78M |
| FY2022 | USD 2.21B | -USD 270.58M | USD 18.69M | 35.5% | -0.86 | USD 25.98M | USD 2.62B | USD 298.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 5.72B | 37.4 | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.96B | 57.3 | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.45B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.86B | 101.2 | n/a | n/a |
| 2022 | 2022-12-30 | USD 301.44M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 715.69M | 68.4 | n/a | n/a |
About Amneal Pharmaceuticals Inc - Class A
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Amneal Pharmaceuticals Inc - Class A overvalued or undervalued?
Bullrun's valuation model currently marks Amneal Pharmaceuticals Inc - Class A as 35.6% overvalued.
What is Amneal Pharmaceuticals Inc - Class A's market cap?
Amneal Pharmaceuticals Inc - Class A's market capitalization is USD 5.72B.
What is Amneal Pharmaceuticals Inc - Class A's P/E ratio?
Amneal Pharmaceuticals Inc - Class A's price-to-earnings (P/E) ratio is 37.4.
What does Amneal Pharmaceuticals Inc - Class A do?
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.